HtrA3 Antibody

Immunohistochemistry (FFPE): 1:25, Western blot: 1:500-1:2000

The stated application concentrations are suggested starting points. Titration of the HtrA3 antibody may be required due to differences in protocols and secondary/substrate sensitivity.

Insulin-like growth factors (IGFs) stimulate the proliferation and differentiation of a vast number of cell types. The action of the growth factors is mediated and controlled by a complex system of components, including several proteases that cleave the IGF-Binding Proteins. HtrA1 is a 480 aa protein that contains an N-terminus homologous to MAC25 (IGFBP7) with a conserved Kazal-type serine protease inhibitor motif, as well as a C-terminal PDZ domain. Semiquantitative RT-PCR and immunoblot analyses showed an approximately 7-fold increase of PRSS11 in osteoarthritis cartilage compared with controls. HTRA2 is released from mitochondria and inhibits the function of XIAP by direct binding in a way similar to SMAC. Moreover, when overexpressed extramitochondrially, HTRA2 induced atypical cell death, which was neither accompanied by a significant increase in caspase activity nor inhibited by caspase inhibitors, including XIAP. A catalytically inactive mutant of HTRA2, however, did not induce cell death. Suzuki et al. (2001) concluded that HTRA2 is a SMAC-like inhibitor of IAP (inhibitor of apoptosis proteins) activity with a serine protease-dependent cell death-inducing activity.

Purified

In 1X PBS, pH 7.4, with 0.09% sodium azide

A portion of amino acids 112-144 from the human protein was used as the immunogen for the HtrA3 antibody.

This HtrA3 antibody is available for research use only.

Nuclear, cytoplasmic

Purified

Human, Rat

P83110